Haemopoietic growth factors in myelodysplastic syndromes: Towards patient-oriented therapy?

Journal of Experimental and Clinical Cancer Research

Volumn 24, Issue 1, 2005, Pages 5-16

  Clavio, M ^a   Balleari, E ^a   Garrone, A ^a   Ballerini, F ^a   Varaldo, R ^a   Michelis, G L ^a   Balocco, M ^a   Abdall, N ^a   Colombo, N ^a   Grasso, R ^a   Gobbi, Marco ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Anaemia; Erythropoietin; G CSF; Myelodysplastic syndromes

Indexed keywords

AMSACRINE; CYTARABINE; ERYTHROPOIETIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; HEMOGLOBIN; HEMOPOIETIC GROWTH FACTOR; IDARUBICIN; INTERLEUKIN 3; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; CELL CYCLE S PHASE; CELL GROWTH; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TOLERABILITY; ERYTHROID CELL; HIGH RISK POPULATION; HUMAN; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

ANEMIA; HEMATOPOIETIC CELL GROWTH FACTORS; HUMANS; MYELODYSPLASTIC SYNDROMES; NEUTROPENIA; RISK FACTORS;

EID: 20844442621     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Heaney M.L. and Golds D.W.: Myelodysplasia. N. Eng. J. Med. 340:1649-1660, 1999.
2. Bennett J.M., Catowsky D., Daniel M.T. et al.: Proposals for the classification of myelodysplastic syndromes. Br. J. Haematol. 51:189-199, 1982.
3. Harris N.L., Jaffe E.S., Diebold J. et al.: World Health Organization classification of neoplastic diseases of the Hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting - Airlie House, Virginia, November 1997. J. Clin. Oncol. 17:3835-3849, 1999.
4. Vardiman J.W., Harris N.L. and Brunning R.D.: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292-2302, 2002.
5. Greenberg P., Cox C., LeBeau M.M. et al.: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997.
6. Sanz G.F., Sanz M.A., Vallespi T. et al.: Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 74:395-408, 1989.
7. Cazzola M., Ponchio L., Beguin Y. et al.: Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial. Blood 79:29-37, 1992.
8. Cazzola M., Messinger D., Battistel V. et al.: Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 86:4446-4453, 1995.
9. Osterborg A., Boogaerts M.A., Cimino R. et al.: Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Blood 87:2675-2682, 1996.
10. Glaspy J., Bukowski R., Steinberg D., Taylor C., Tchekmedyian S. and Vadhan-Raj S.: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J. Clin. Oncol. 15:1218-1234, 1997.
11. Portenoy R.K. and Itri L.M.: Cancer-related fatigue: guidelines for evaluation and management. Oncologist 4:1-10, 1999.
12. Aapro M.S., Cella D. and Zagari M.: Age, anemia, and fatigue. Semin. Oncol. 29(3 Suppl 8):55-59, 2002.
13. Merchav S., Nielsen O.J., Rosenbaum H. et al.: In vitro studies of erythropoietin-dependent regulation of erythropoiesis in myelodysplastic syndromes. Leukemia 4:771-774, 1990.
14. Demetri G.D., Kris M., Wade J., Degos L., and Cella D.: Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J. Clin. Oncol. 16:3412-3425, 1998.
15. Quirt I., Robeson C., Lau C.Y. et al.: (Eprex Oncology Study Group) Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J. Clin. Oncol. 19:4126-4134, 2001.
16. Cella D., Zagari M.J., Vandoros C., Gagnon D.D., Hurtz H.J. and Nortier J.W.: Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J. Clin. Oncol. 21:366-373, 2003.
17. Asano H., Ohashi H., Ichihara M. et al.: Evidence for nonclonal hematopoietic progenitor cell populations in bone marrow of patients with myelodysplastic syndromes. Blood 84:588-594, 1994.
18. Aoki A. and Shibata A.: In vitro study of erythropoiesis in patients with aplastic anemia and myelodysplastic syndromes: a possible tool for prospective determination of the clinical effectiveness of growth factors. Hematol. Patho. 16:143-153, 1992.
19. Cheson B.D., Bennett J.M., Kantarjian H. et al.: World Health Organization(WHO) international working group. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96:3671-3674, 2000.
20. Bessho M., Itoh Y., Kataumi S. et al.: Improvement of anemia by recombinant erythropoietin in patients with myelodysplastic syndromes and aplastic anemia. Int. J. Cell. Cloning 8:445-458, 1990.
21. Stein R.S., Abels R.I. and Krantz S.B.: Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. Blood 78:1658-1663, 1991.
22. Bowen D., Culligan D. and Jacobs A.: The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietin. Br. J. Haematol. 77:419-423, 1991.
23. Adamson J.W., Schuster M., Allen S. and Haley N.R.: Effectiveness of recombinant human erythropoietin therapy in myelodysplastic syndromes. Acta Haematol. 87 Suppl 1:20-24, 1992.
24. Musto P., Catalano L., Andriani A. et al.: Recombinant erythropoietin for refractory anemia with ring sideroblasts. Haematologica 77:185-186, 1992.
25. Ghio R., Balleari E., Ballestrero A. et al.: Subcutaneous recombinant human erythropoietin for the treatment of anemia in myelodysplastic syndromes. Acta Haematol. 90:58-64, 1993.
26. Aloe Spiriti M.A., Petti M.C., Latagliata R. et al.: Recombinant human erythropoietin in the treatment of myelodysplastic syndromes. An interim report. Haematologica 78:123-126, 1993.
27. Isnard F., Najman A., Jaar B. et al.: Efficacy of recombinant human erythropoietin in the treatment of refractory anemias without excess of blasts in myelodysplastic syndromes. Leuk. Lymphoma 12(3-4):307-314, 1994.
28. Rose E.H., Abels R.I., Nelson R.A., McCullough D.M. and Lessin L.: The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS). Br. J. Haematol. 89:831-837, 1995.
29. Razzano M., Caslini C., Cortelazzo S., Battistel V., Rambaldi A. and Barbui T.: Clinical and biological effects of erythropoietin treatment of myelodysplastic syndrome. Leuk. Lymphoma 10:127-134, 1993.
30. Stasi R., Brunetti M., Bussa S. et al.: Response to recombinant human erythropoietin in patients with myelodysplastic syndromes. Clin. Cancer Res. 3:733-7339, 1997.
31. Hellstrom-Lindberg E.: Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br. J. Haematol. 89:67-71, 1995.
32. Italian cooperative study group for rHuEpo in myelodysplastic syndromes.: A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br. J. Haematol. 103:1070-1074, 1998.
33. Backx B., Broeders L. and Lowenberg B.: Kit ligand improves in vitro erythropoiesis in myelodysplastic syndrome. Blood 80:1213-1217, 1992.
34. Donahue R.E., Emerson S.G., Wang E.A., Wong G.G., Clark S.C. and Nathan D.G.: Demonstration of burst-promoting activity of recombinant human GM-CSF on circulating erythroid progenitors using an assay involving the delayed addition of erythropoietin. Blood 66:1479-1481, 1985.
35. Negrin R.S., Stein R., Vardiman J. et al.: Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood 82:737-743, 1993.
36. Hellstrom-Lindberg E., Birgegard G., Carlsson M. et al.: A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes. Leuk. Lymphoma 11:221-228, 1993.
37. Negrin R.S., Stein R., Doherty K. et al.: Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 87:4076-4081, 1996.
38. Hellstrom-Lindberg E., Negrin R., Stein R. et al.: Erythroid response to treatment with G-CSF plus erythropoietin for the anemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br. J. Haematol. 99:344-351, 1997.
39. Economopoulos T., Mellou S., Papageorgiou E. et al.: Treatment of anemia in low risk myelodysplastic syndromes with granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin. Leukemia 13:1009-1012, 1999.
40. Stasi R., Pagano A., Terzoli E. and Amadori S.: Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes. Br. J. Haematol. 105:141-148, 1999.
41. Thompson J.A., Gilliland D.G., Prchal J.T. et al.: Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. GM/EPO MDS Study Group. Blood 95:1175-1179, 2000.
42. Remacha A.F., Arrizabalaga B., Villegas A. et al.: Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group. Haematologica 84:1058-1064, 1999.
43. Bernell P., Stenke L., Wallvik J., Hippe E. and Hast R.A.: Sequential erythropoietin and GM-CSF schedule offers clinical benefits in the treatment of anaemia in myelodysplastic syndromes. Leuk. Res. 20:693-699, 1996.
44. Musto P., Sanpaolo G., D'Arena G. et al.: Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone. Haematologica 86:44-51, 2001.
45. Hellstrom-Lindberg E., Ahlgren T., Beguin Y. et al.: Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 92:68-75, 1998.
46. Kasper C., Zahner J. and Sayer H.G.: Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. J. Cancer Res. Clin. Oncol. 128:497-502, 2002.
47. Terpos E., Mougiou A., Kouraklis A. et al. for The Greek MDS Study Group: Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. Br. J. Haematol. 118:174-180, 2002.
48. Mantovani L., Lentini G., Hentschel B., et al.: Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin. Br. J. Haematol. 109:367-375, 2000.
49. Cheung W.K., Minton N. and Gunawardena K.: Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly. Eur. J. Clin. Pharmacol. 57:411-418, 2001.
50. Cheung W.K., Goon B.L., Guilfoyle M.C. and Wacholtz M.C.: Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects. Clin. Pharmacol. Ther. 64:412-423, 1998.
51. Gabrilove J.L., Cleeland C.S., Livingston R.B., Sarokhan B., Winer E. and Einhorn L.H.: Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J. Clin. Oncol. 19:2875-2882, 2001.
52. Cazzola M., Coiffier B., Kloczko J. and Spika I.: Once weekly Neorecormon (epoetin beta) for the treatment of anemia associated with lymphoproliferative malignancies: results of the NOW (Neorecormon once-weekly) study. The Hematol. J. 3:64-66, 2002.
53. Aloe Spiriti M.A. for the Italian Fatigue-QoL/MDS Cooperative Group, Italy.: Effects of 40,000 IU biweekly induction dose of epoetin alfa followed by 40,000 IU once weekly in low-risk myelodysplastic syndrome patients (abstract). Blood 100 (suppl 1):790a, 2002.
54. Musto P., Falcone A., Sanpaolo G. et al.: Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes. Br. J. Haematol. 122:269-271, 2003.
55. Stasi R., Brunetti M., Terzoli E., Amadori S.: Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes. Blood 99:1578-1584, 2002.
56. Hesketh P.J., Arena F., Patel D. et al.: A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. Cancer 100:859-868, 2004.
57. Cella D.: The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin. Hematol. 34(3 Suppl 2):13-19, 1997.
58. Hellstrom-Lindberg E., Gulbrandsen N., Lindberg G. et al. Scandinavian MDS Group: A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br. J. Haematol. 120:1037-1046, 2003.
59. Casadewal N., Durieux P., Dubois S. et al, pour le Groupe Francais des Myelodysplasies: Erythropoietin (rHuEpo) plus G-CSF in the treatment of anemia in myelodysplastic syndromes (MDS): results of a randomized trial with impact on quality of life and costs. Blood 98 (suppl 1):3521 a.
60. Clavio M., Nobili F., Balleari E. et al.: Quality of life and brain function following high-dose recombinant human erythropoietin in low-risk myelodysplastic syndromes: a preliminary report. Eur. J. Haematol. 72:113-120, 2004.
61. Ludwig H., Fritz E., Leitgeb C. et al.: Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 84:1056-1063, 1994.
62. Henry D.H. and Abels R.I.: Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies. Semin. Oncol. 21 (2 Suppl 3):21-28, 1994.
63. Cazzola M., Ponchio L., Pedrotti C. et al.: Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancies. Haematologica 81:431-441, 1996.
64. Adamson J.W., Ludwig H.: Predicting the hematopoietic response to recombinant human erythropoietin (epoetin alfa) in the treatment of anemia of cancer. Oncology 56:46-53, 1999.
65. Beguin Y.: Prediction of response to optimize outcome of treatment with erythropoietin. Semin. Oncol. 25 (Suppl 7):27-34, 1998.
66. Howe R.B., Porwit-MacDonald A., Wanat R., Tehranchi R. and Hellstrom-Lindberg E.: The WHO classification of MDS does make a difference. Blood 103:3265-3270, 2004.
67. Alessandrino E.P., Amadori S., Barosi G. et al.: Evidence and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Haematology. Haematologica 87:1286-1306, 2002.
68. Bowen D., Culligan D., Jowitt S. et al.: Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br. J. Haematol. 120:187-200, 2003.
69. Negrin R.S., Haeuber D.H., Nagler A. and Kobayashi Y. et al.: Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 76:36-43, 1990.
70. Yoshida Y., Nakahata T., Shibata A. et al.: Effects of long term treatment with recombinant human granulocyte-macrophage colony stimulating factor in patients with myelodysplastic syndrome. Leuk. Lymphoma 18:457-463, 1995.
71. Willemze R., van der Lely N., Zwierzina H. et al.: A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. EORTC Leukemia Cooperative Group. Ann. Hematol. 64:173-180, 1992.
72. Tafuri A. and Andreeff M.: Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 4:826-834, 1990.
73. Reuter C., Auf der Landwehr U., Schleyer E. et al.: Modulation of intracellular metabolism of cytosine arabinoside in acute myeloid leukemia by granulocyte-macrophage colony-stimulating factor. Leukemia 8:217-225, 1994.
74. Plunkett W. and Saunders P.P.: Metabolism and action of purine nucleoside analogs. Pharmacol. Ther. 49:239-268, 1991.
75. Gandhi V., Estey E., Keating M.J. and Plunkett W.: Biochemical modulation of arabinosylcytosine for therapy of leukemias. Leuk. Lymphoma 10 Suppl:109-114, 1993.
76. Tosi P., Visani G., Ottaviani E., Manfori S., Zinzani P.L. and Tura S.: Fludarabine + Ara-C + G-CSF: cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells. Leukemia 8:2076-2082, 1994.
77. Estey E., Thall P.F., Kantarjian H. et al.: Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF. Blood 79:2246-2255, 1992.
78. Estey E., Thall P., Andreeff M. et al.: Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J. Clin. Oncol. 12:671-678, 1994.
79. Estey E.H., Thall P.F., Pierce S. et al.: Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 93:2478-2484, 1999.
80. Hast R., Hellstrom-Lindberg E., Ohm L. et al.: No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease. Leukemia 17:1827-1833, 2003.
81. Ferrara F., Leoni F., Pinto A. et al.: Fludarabine, cytarabine, and granulocyte-colony stimulating factor for the treatment of high risk myelodysplastic syndromes. Cancer 86:2006-2013, 1999.
82. Lowenberg B., van Putten W., Theobald M. et al.: Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N. Engl. J. Med. 349:743-752, 2003.
83. Buchner T., Berdel W.E., Hiddemann W.: Priming with granulocyte colony-stimulating factor-relation to high-dose cytarabine in acute myeloid leukemia. N. Engl. J. Med. 350:2215-2216, 2004.